Tags

Type your tag names separated by a space and hit enter

Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma.
Int J Mol Sci. 2021 Apr 06; 22(7)IJ

Abstract

Glaucoma is a progressive neurodegenerative disease which constitutes the main frequent cause of irreversible blindness. Recent findings have shown that oxidative stress, inflammation and glutamatergic pathway play key roles in the causes of glaucoma. Recent studies have shown a down regulation of the WNT/β-catenin pathway in glaucoma, associated with overactivation of the GSK-3β signaling. WNT/β-catenin pathway is mainly associated with oxidative stress, inflammation and glutamatergic pathway. Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa plant which possesses many therapeutic properties across a range of neuropsychiatric disorders. Since few years, CBD presents an increased interest as a possible drug in anxiolytic disorders. CBD administration is associated with increase of the WNT/β-catenin pathway and decrease of the GSK-3β activity. CBD has a lower affinity for CB1 but can act through other signaling in glaucoma, including the WNT/β-catenin pathway. CBD downregulates GSK3-β activity, an inhibitor of WNT/β-catenin pathway. Moreover, CBD was reported to suppress pro-inflammatory signaling and neuroinflammation, oxidative stress and glutamatergic pathway. Thus, this review focuses on the potential effects of cannabidiol, as a potential therapeutic strategy, on glaucoma and some of the presumed mechanisms by which this phytocannabinoid provides its possible benefit properties through the WNT/β-catenin pathway.

Authors+Show Affiliations

Department of Clinical Research and Innovation (DRCI), Foch Hospital, 92150 Suresnes, France.Centre de Recherche Clinique, Grand Hôpital de l'Est Francilien (GHEF), 6-8 rue Saint-Fiacre, 77100 Meaux, France.Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80054 Amiens, France. Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, 86000 Poitiers, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33917605

Citation

Vallée, Alexandre, et al. "Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma." International Journal of Molecular Sciences, vol. 22, no. 7, 2021.
Vallée A, Lecarpentier Y, Vallée JN. Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma. Int J Mol Sci. 2021;22(7).
Vallée, A., Lecarpentier, Y., & Vallée, J. N. (2021). Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma. International Journal of Molecular Sciences, 22(7). https://doi.org/10.3390/ijms22073798
Vallée A, Lecarpentier Y, Vallée JN. Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma. Int J Mol Sci. 2021 Apr 6;22(7) PubMed PMID: 33917605.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma. AU - Vallée,Alexandre, AU - Lecarpentier,Yves, AU - Vallée,Jean-Noël, Y1 - 2021/04/06/ PY - 2021/02/08/received PY - 2021/03/21/revised PY - 2021/03/22/accepted PY - 2021/4/30/entrez PY - 2021/5/1/pubmed PY - 2021/5/13/medline KW - WNT/β-catenin pathway KW - cannabidiol KW - glaucoma KW - glutamatergic pathway KW - inflammation KW - oxidative stress JF - International journal of molecular sciences JO - Int J Mol Sci VL - 22 IS - 7 N2 - Glaucoma is a progressive neurodegenerative disease which constitutes the main frequent cause of irreversible blindness. Recent findings have shown that oxidative stress, inflammation and glutamatergic pathway play key roles in the causes of glaucoma. Recent studies have shown a down regulation of the WNT/β-catenin pathway in glaucoma, associated with overactivation of the GSK-3β signaling. WNT/β-catenin pathway is mainly associated with oxidative stress, inflammation and glutamatergic pathway. Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa plant which possesses many therapeutic properties across a range of neuropsychiatric disorders. Since few years, CBD presents an increased interest as a possible drug in anxiolytic disorders. CBD administration is associated with increase of the WNT/β-catenin pathway and decrease of the GSK-3β activity. CBD has a lower affinity for CB1 but can act through other signaling in glaucoma, including the WNT/β-catenin pathway. CBD downregulates GSK3-β activity, an inhibitor of WNT/β-catenin pathway. Moreover, CBD was reported to suppress pro-inflammatory signaling and neuroinflammation, oxidative stress and glutamatergic pathway. Thus, this review focuses on the potential effects of cannabidiol, as a potential therapeutic strategy, on glaucoma and some of the presumed mechanisms by which this phytocannabinoid provides its possible benefit properties through the WNT/β-catenin pathway. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/33917605/Cannabidiol_and_the_Canonical_WNT/β_Catenin_Pathway_in_Glaucoma_ L2 - https://www.mdpi.com/resolver?pii=ijms22073798 DB - PRIME DP - Unbound Medicine ER -